Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The MICA/MICB and ULBP (UL16-binding protein) families represent the primary human ligands for the activating receptor NKG2D (Natural Killer Group 2 Member D), which is expressed on natural killer (NK) cells, CD8+ T cells, and gd T cells. Under normal physiological conditions, these stress-induced ligands are virtually absent or expressed at very low levels on healthy tissues. However, they are significantly upregulated on the surface of cells undergoing oncogenic transformation, viral infection, or genotoxic stress, serving as a 'kill me' signal that triggers immune-mediated destruction. In many cancers, tumor cells evade this immunosurveillance by utilizing matrix metalloproteinases (MMPs) and ADAM family proteases to proteolytically cleave (shed) MICA/MICB and ULBPs from their cell surface. The resulting soluble ligands act as immunosuppressive decoys that bind to and downregulate NKG2D on cytotoxic lymphocytes, leading to immune evasion.
Therapeutic strategies targeting the MICA/MICB and ULBP family aim to restore or enhance the NKG2D-mediated anti-tumor immune response. Monoclonal antibodies, such as CLN-619 and DM-919, are designed to bind the membrane-proximal a3 domain of MICA/MICB, thereby preventing proteolytic shedding, stabilizing surface expression, and promoting antibody-dependent cellular cytotoxicity (ADCC). Other approaches include antibodies like 23ME-01473 that target the ULBP family (specifically ULBP6/2/5) to neutralize soluble decoys and stimulate NK cell activation. Additionally, cellular immunotherapies, such as CAR-T (e.g., CYAD-01) and CAR-NK (e.g., NKX101) cells engineered with NKG2D-based chimeric receptors, are being developed to directly target and eliminate tumor cells expressing these ligands. These therapies hold significant promise, particularly for treating tumors that have lost MHC class I expression and are resistant to conventional checkpoint inhibitors.
Inhibition of proteolytic shedding of MICA/MICB and ULBPs, neutralization of soluble NKG2D ligands, induction of antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), and chimeric antigen receptor (CAR) mediated targeting and activation of cytotoxic lymphocytes.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer group 2 member D ligand (NKG2DL).